Seres Therapeutics Presents Three Posters at DDW Conference
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
SERES Debuts Intelligent Safety at Auto Shanghai 2025, Setting Industry Standard and Capturing Global Spotlight
$MCRB Stock Is up 24% Today. Here's What We See in Our Data.
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Seres Therapeutics Trading Halted, News Pending
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Seres Therapeutics To Carry Out 1-for-20 Reverse Stock Split On April 22nd, 2025
12 Health Care Stocks Moving In Monday's After-Market Session
Seres Therapeutics Approves Reverse Stock Split Plan
Seres Therapeutics Price Target Maintained With a $1.25/Share by Chardan Capital
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Piper Sandler Downgrades Seres Therapeutics(MCRB.US) to Hold Rating, Cuts Target Price to $1
Express News | Goldman Sachs Maintains Sell on Seres Therapeutics, Lowers Price Target to $0.75
Seres Therapeutics Analyst Ratings
Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?
Seres Therapeutics (MCRB) Gets a Hold From Piper Sandler
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating